Pathways Beyond Oncology Resource Center

Clinical Pathways GPS

Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease

03/16/2020

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...

...

03/16/2020

Journal of Clinical Pathways

Clinical Pathways GPS

Speaker Pelosi’s Plan to Lower Drug Costs

11/18/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

As total cost of care increasingly becomes a major issue in the United States, both market solutions like clinical pathways and government solutions such as drug pricing regulations are being proposed. Each solution...

As...

11/18/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Ramifications of “Medicare for All” and Implications for Clinical Pathways

08/19/2019

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and...

As the...

08/19/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Engaging Patients in Care Through Greater Access to Medical Records and Clinical Pathways

04/16/2019

Kristin LaBounty Phillips , MPH;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Shay L. Ashline , PhD;

Matthew Pakizegee , PharmD, MS;

Without interoperability of medical records between health systems, patients are the best chance for the medical system to provide continuity of care when medical records from a different health system are difficult...

...

04/16/2019

Journal of Clinical Pathways

Perspectives

Getting “Bundle Ready”: How Provider Organizations Can Design Clinical Pathways in the Context of Bundled Payments

02/19/2019

Joshua M. Liao , MD, MSc, FACP;

Christopher P. Chen , MD, MBA;

Abstract: Clinical pathways can be meaningful tools for improving the quality and value of care. Pathway initiatives are also influenced by payment policy, taking different forms and adopting different emphases...

...

02/19/2019

Journal of Clinical Pathways

Clinical Pathways GPS

Value-Based Clinical Pathways in the World of Reference-Priced Medicare Part B Drugs

12/13/2018

Matthew Pakizegee , PharmD, MS;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The Centers for Medicare & Medicaid Services (CMS) released an advanced notice of proposed rulemaking on October 25, 2018, seeking to test  whether using a combination of 3 approaches—an international drug...

The...

12/13/2018

Journal of Clinical Pathways

Clinical Pathways GPS

How the Proposed Elimination of Medicare Rebates Would Impact Clinical Pathways

11/18/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

The Centers for Medicare & Medicaid Services (CMS) has published a range of new proposed and final rules regarding payment rates and policies affecting providers, payers, and patients. The Trump administration...

The...

11/18/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Understanding the "American Patients First‚" Blueprint: Implications for Clinical Pathways

06/14/2018

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

With the release of President Trump’s “American Patients First” strategy blueprint to tackle US drug pricing and health care costs, clinical pathway developers and professionals will need to take this proposed plan...

With...

06/14/2018

Journal of Clinical Pathways

Department

A Heart Failure Clinical Pathway to Reduce Hospital Readmissions

03/15/2018

JCP Editors

Heart failure (HF) is the primary diagnosis in over 1 million hospitalizations annually,1 and patients who are hospitalized for HF are at high risk for all-cause hospital readmission, with a 1-month readmission rate...

Heart...

03/15/2018

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Recent Stories

Research Reports

Post–COVID-19 Syndrome Clinical Pathway for the US Veterans Health Administration

02/06/2023

Allison M. Gustavson , DPT, PhD;

Johnson Vachachira , NP;

Claudia L. Campos , MD;

Jacob B. Lindheimer , PhD;

Kristina Crothers , MD;

Omar Awan , MD;

Carrie B. May , PsyD;

Cristina Nguyen , BS;

Courtney Sedillo , MSN, FNP-C;

Francis J. Miller Jr., MD;

Lindheimer et al summarize the stepwise diagnostic approach for patients presenting with PCS dyspnea and/or cough in primary care and highlight teleconsultation and telerehabilitation as opportunities to reach those in rural areas or with...

Lindheimer et al summarize the...

02/06/2023

Journal of Clinical Pathways